

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=088 (081) Huddinge

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|-------------|-------------|-------------|-------------|------------|-------------|------------|-------------|-----------|-------------|-----------|-------------|------------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 311 | 0.4% | 34 | 0.0% | 12 | 0.0% | 4 | 0.0% | . | . | 2 | 0.0% | 17 | 0.0% | 70173 | 99.5% | 70553 | 100.0% |
| ASCUS | 302 | 15.6% | 347 | 18.0% | 155 | 8.0% | 140 | 7.3% | 3 | 0.2% | 4 | 0.2% | 156 | 8.1% | 824 | 42.7% | 1931 | 100.0% |
| CIN1 | 330 | 20.2% | 499 | 30.5% | 200 | 12.2% | 163 | 10.0% | 4 | 0.2% | 3 | 0.2% | 136 | 8.3% | 302 | 18.4% | 1637 | 100.0% |
| Körtelcellsatypi | 67 | 34.9% | 23 | 12.0% | 17 | 8.9% | 37 | 19.3% | 10 | 5.2% | 6 | 3.1% | 20 | 10.4% | 12 | 6.3% | 192 | 100.0% |
| Atypi av oklar celltyp | 10 | 37.0% | 2 | 7.4% | 4 | 14.8% | 9 | 33.3% | . | . | . | . | 1 | 3.7% | 1 | 3.7% | 27 | 100.0% |
| ASC-H | 8 | 6.8% | 14 | 11.9% | 20 | 16.9% | 62 | 52.5% | 5 | 4.2% | 6 | 5.1% | 3 | 2.5% | . | . | 118 | 100.0% |
| CIN2 | 61 | 8.8% | 78 | 11.3% | 168 | 24.3% | 320 | 46.3% | 4 | 0.6% | 13 | 1.9% | 25 | 3.6% | 22 | 3.2% | 691 | 100.0% |
| CIN3 | 5 | 2.5% | 3 | 1.5% | 15 | 7.4% | 165 | 81.7% | 1 | 0.5% | 8 | 4.0% | 2 | 1.0% | 3 | 1.5% | 202 | 100.0% |
| Adenocarcinom | 4 | 10.8% | 3 | 8.1% | . | . | 11 | 29.7% | 7 | 18.9% | 10 | 27.0% | 1 | 2.7% | 1 | 2.7% | 37 | 100.0% |
| Skivepitelcancer | . | . | . | . | . | . | 6 | 37.5% | . | . | 9 | 56.3% | . | . | 1 | 6.3% | 16 | 100.0% |
| Totalt | 1098 | 1.5% | 1003 | 1.3% | 591 | 0.8% | 917 | 1.2% | 34 | 0.0% | 61 | 0.1% | 361 | 0.5% | 71339 | 94.6% | 75404 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=121 Uppsala

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------|--------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|-------|-------|-------|------------|-------|--------|--------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 58 | 0.6% | 18 | 0.2% | 8 | 0.1% | 3 | 0.0% | . | . | . | . | 8 | 0.1% | 10378 | 99.1% | 10473 | 100.0% |
| ASCUS | 14 | 5.5% | 34 | 13.4% | 24 | 9.5% | 31 | 12.3% | 5 | 2.0% | 2 | 0.8% | 2 | 0.8% | 141 | 55.7% | 253 | 100.0% |
| CIN1 | 41 | 12.8% | 100 | 31.2% | 54 | 16.8% | 64 | 19.9% | 2 | 0.6% | 6 | 1.9% | 3 | 0.9% | 51 | 15.9% | 321 | 100.0% |
| Körtelcellsatypi | 2 | 25.0% | 2 | 25.0% | 2 | 25.0% | 1 | 12.5% | . | . | . | . | . | . | 1 | 12.5% | 8 | 100.0% |
| CIN2 | . | . | 3 | 7.7% | 5 | 12.8% | 25 | 64.1% | 1 | 2.6% | 3 | 7.7% | . | . | 2 | 5.1% | 39 | 100.0% |
| CIN3 | 2 | 6.5% | 1 | 3.2% | . | . | 23 | 74.2% | 1 | 3.2% | 4 | 12.9% | . | . | . | . | 31 | 100.0% |
| Totalt | 117 | 1.1% | 158 | 1.4% | 93 | 0.8% | 147 | 1.3% | 9 | 0.1% | 15 | 0.1% | 13 | 0.1% | 10573 | 95.0% | 11125 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=131 Eskilstuna

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|--------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|-------|-------|-------|------------|-------|--------|--------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 92 | 0.6% | 6 | 0.0% | 3 | 0.0% | 2 | 0.0% | . | . | . | . | 5 | 0.0% | 14994 | 99.3% | 15102 | 100.0% |
| ASCUS | 34 | 27.4% | 35 | 28.2% | 14 | 11.3% | 9 | 7.3% | . | . | . | . | 6 | 4.8% | 26 | 21.0% | 124 | 100.0% |
| CIN1 | 20 | 30.3% | 17 | 25.8% | 7 | 10.6% | 9 | 13.6% | . | . | . | . | 4 | 6.1% | 9 | 13.6% | 66 | 100.0% |
| Körtelcellsatypi | 2 | 50.0% | 1 | 25.0% | . | . | . | . | 1 | 25.0% | . | . | . | . | . | . | 4 | 100.0% |
| Atypi av oklar celltyp | . | . | 3 | 42.9% | 1 | 14.3% | 1 | 14.3% | . | . | . | . | . | . | 2 | 28.6% | 7 | 100.0% |
| ASC-H | . | . | 1 | 12.5% | 3 | 37.5% | 2 | 25.0% | . | . | 1 | 12.5% | . | . | 1 | 12.5% | 8 | 100.0% |
| CIN2 | 2 | 5.0% | 4 | 10.0% | 11 | 27.5% | 17 | 42.5% | . | . | 1 | 2.5% | 4 | 10.0% | 1 | 2.5% | 40 | 100.0% |
| CIN3 | . | . | 2 | 8.3% | 5 | 20.8% | 17 | 70.8% | . | . | . | . | . | . | . | . | 24 | 100.0% |
| Totalt | 150 | 1.0% | 69 | 0.4% | 44 | 0.3% | 57 | 0.4% | 1 | 0.0% | 2 | 0.0% | 19 | 0.1% | 15033 | 97.8% | 15375 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=211 Linköping

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|-----------|-------------|-----------|-------------|-----------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 72 | 0.3% | 3 | 0.0% | 2 | 0.0% | . | . | . | . | . | . | 5 | 0.0% | 22451 | 99.6% | 22533 | 100.0% |
| ASCUS | 19 | 1.9% | 83 | 8.1% | 35 | 3.4% | 41 | 4.0% | 1 | 0.1% | . | . | 3 | 0.3% | 841 | 82.2% | 1023 | 100.0% |
| CIN1 | 18 | 3.6% | 92 | 18.1% | 25 | 4.9% | 54 | 10.7% | 1 | 0.2% | . | . | 5 | 1.0% | 312 | 61.5% | 507 | 100.0% |
| Körtelcellsatypi | 12 | 27.9% | 9 | 20.9% | 4 | 9.3% | 4 | 9.3% | 5 | 11.6% | 1 | 2.3% | . | . | 8 | 18.6% | 43 | 100.0% |
| Atypi av oklar celltyp | . | . | 1 | 50.0% | . | . | . | . | . | . | . | . | . | . | 1 | 50.0% | 2 | 100.0% |
| ASC-H | 1 | 11.1% | . | . | 3 | 33.3% | 5 | 55.6% | . | . | . | . | . | . | . | . | 9 | 100.0% |
| CIN2 | 2 | 1.6% | 6 | 4.9% | 33 | 27.0% | 72 | 59.0% | 2 | 1.6% | 3 | 2.5% | 1 | 0.8% | 3 | 2.5% | 122 | 100.0% |
| CIN3 | . | . | . | . | 5 | 5.8% | 71 | 82.6% | 3 | 3.5% | 5 | 5.8% | 1 | 1.2% | 1 | 1.2% | 86 | 100.0% |
| Adenocarcinom | . | . | . | . | . | . | . | . | 3 | 75.0% | 1 | 25.0% | . | . | . | . | 4 | 100.0% |
| Skivepitelcancer | . | . | . | . | . | . | . | . | . | . | 2 | 100.0% | . | . | . | . | 2 | 100.0% |
| Totalt | 124 | 0.5% | 194 | 0.8% | 107 | 0.4% | 247 | 1.0% | 15 | 0.1% | 12 | 0.0% | 15 | 0.1% | 23617 | 97.1% | 24331 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=231 Jönköping

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|----------|-------------|----------|-------------|-----------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 101 | 0.5% | 5 | 0.0% | 3 | 0.0% | 1 | 0.0% | 1 | 0.0% | 1 | 0.0% | 1 | 0.0% | 18721 | 99.4% | 18834 | 100.0% |
| ASCUS | 75 | 18.5% | 74 | 18.3% | 42 | 10.4% | 25 | 6.2% | . | . | . | . | 25 | 6.2% | 164 | 40.5% | 405 | 100.0% |
| CIN1 | 44 | 18.4% | 66 | 27.6% | 35 | 14.6% | 24 | 10.0% | . | . | . | . | 10 | 4.2% | 60 | 25.1% | 239 | 100.0% |
| Körtelcellsatypi | 1 | 11.1% | 1 | 11.1% | 2 | 22.2% | 3 | 33.3% | . | . | 2 | 22.2% | . | . | . | . | 9 | 100.0% |
| Atypi av oklar celltyp | 1 | 100.0% | . | . | . | . | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% |
| ASC-H | 2 | 10.5% | . | . | 1 | 5.3% | 14 | 73.7% | . | . | . | . | . | . | 2 | 10.5% | 19 | 100.0% |
| CIN2 | 5 | 5.1% | 3 | 3.0% | 29 | 29.3% | 57 | 57.6% | 2 | 2.0% | . | . | . | . | 3 | 3.0% | 99 | 100.0% |
| CIN3 | . | . | 2 | 4.0% | 4 | 8.0% | 40 | 80.0% | . | . | 3 | 6.0% | . | . | 1 | 2.0% | 50 | 100.0% |
| Totalt | 229 | 1.2% | 151 | 0.8% | 116 | 0.6% | 164 | 0.8% | 3 | 0.0% | 6 | 0.0% | 36 | 0.2% | 18951 | 96.4% | 19656 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=241 Växjö

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|--------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|-------|-------|-------|------------|-------|--------|--------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 71 | 0.9% | . | . | . | . | . | . | . | . | 1 | 0.0% | . | . | 7665 | 99.1% | 7737 | 100.0% |
| ASCUS | 35 | 26.9% | 7 | 5.4% | 7 | 5.4% | 9 | 6.9% | . | . | . | . | . | . | 72 | 55.4% | 130 | 100.0% |
| CIN1 | 32 | 27.8% | 7 | 6.1% | 11 | 9.6% | 11 | 9.6% | . | . | 1 | 0.9% | . | . | 53 | 46.1% | 115 | 100.0% |
| Körtelcellsatypi | 1 | 50.0% | . | . | . | . | . | . | 1 | 50.0% | . | . | . | . | . | . | 2 | 100.0% |
| Atypi av oklar celltyp | . | . | 1 | 20.0% | . | . | 2 | 40.0% | . | . | . | . | . | . | 2 | 40.0% | 5 | 100.0% |
| CIN2 | 5 | 12.2% | 1 | 2.4% | 4 | 9.8% | 28 | 68.3% | . | . | . | . | . | . | 3 | 7.3% | 41 | 100.0% |
| CIN3 | . | . | . | . | . | . | 2 | 50.0% | . | . | 2 | 50.0% | . | . | . | . | 4 | 100.0% |
| Totalt | 144 | 1.8% | 16 | 0.2% | 22 | 0.3% | 52 | 0.6% | 1 | 0.0% | 4 | 0.0% | . | . | 7795 | 97.0% | 8034 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=251 Kalmar

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|-----------|-------------|------------|-------------|-----------|-------------|------------|-------------|----------|-------------|----------|-------------|-----------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 48 | 0.4% | 5 | 0.0% | 1 | 0.0% | . | . | . | . | . | . | 8 | 0.1% | 13272 | 99.5% | 13334 | 100.0% |
| ASCUS | 16 | 4.4% | 31 | 8.5% | 23 | 6.3% | 20 | 5.5% | . | . | 1 | 0.3% | 27 | 7.4% | 246 | 67.6% | 364 | 100.0% |
| CIN1 | 17 | 5.8% | 63 | 21.4% | 28 | 9.5% | 23 | 7.8% | . | . | . | . | 35 | 11.9% | 128 | 43.5% | 294 | 100.0% |
| Körtelcellsatypi | . | . | 1 | 7.7% | 1 | 7.7% | 4 | 30.8% | 1 | 7.7% | 2 | 15.4% | 3 | 23.1% | 1 | 7.7% | 13 | 100.0% |
| Atypi av oklar celltyp | 2 | 13.3% | 2 | 13.3% | 1 | 6.7% | 4 | 26.7% | . | . | . | . | 3 | 20.0% | 3 | 20.0% | 15 | 100.0% |
| ASC-H | . | . | 7 | 11.9% | 13 | 22.0% | 35 | 59.3% | . | . | 1 | 1.7% | 2 | 3.4% | 1 | 1.7% | 59 | 100.0% |
| CIN2 | 1 | 4.3% | 3 | 13.0% | 3 | 13.0% | 14 | 60.9% | . | . | . | . | 1 | 4.3% | 1 | 4.3% | 23 | 100.0% |
| CIN3 | 1 | 1.7% | 2 | 3.4% | 3 | 5.2% | 46 | 79.3% | 1 | 1.7% | 4 | 6.9% | . | . | 1 | 1.7% | 58 | 100.0% |
| Adenocarcinom | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | 1 | 100.0% |
| Totalt | 85 | 0.6% | 114 | 0.8% | 73 | 0.5% | 146 | 1.0% | 2 | 0.0% | 9 | 0.1% | 79 | 0.6% | 13653 | 96.4% | 14161 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=271 Karlskrona

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|-----------|-------------|-----------|-------------|-----------|-------------|-----------|-------------|----------|-------------|----------|-------------|-----------|-------------|-------------|--------------|-------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 7 | 0.1% | . | . | . | . | . | . | . | . | 1 | 0.0% | 24 | 0.3% | 7281 | 99.6% | 7313 | 100.0% |
| ASCUS | 3 | 1.5% | 22 | 11.3% | 9 | 4.6% | 3 | 1.5% | . | . | . | . | 13 | 6.7% | 144 | 74.2% | 194 | 100.0% |
| CIN1 | 2 | 1.2% | 42 | 25.8% | 21 | 12.9% | 5 | 3.1% | 1 | 0.6% | . | . | 22 | 13.5% | 70 | 42.9% | 163 | 100.0% |
| Körtelcellsatypi | . | . | . | . | 3 | 33.3% | . | . | 1 | 11.1% | 1 | 11.1% | 2 | 22.2% | 2 | 22.2% | 9 | 100.0% |
| Atypi av oklar celltyp | . | . | 1 | 25.0% | . | . | 2 | 50.0% | . | . | . | . | . | . | 1 | 25.0% | 4 | 100.0% |
| ASC-H | . | . | 7 | 26.9% | 10 | 38.5% | 5 | 19.2% | . | . | . | . | 3 | 11.5% | 1 | 3.8% | 26 | 100.0% |
| CIN2 | . | . | 6 | 11.1% | 27 | 50.0% | 19 | 35.2% | . | . | 1 | 1.9% | . | . | 1 | 1.9% | 54 | 100.0% |
| CIN3 | . | . | 2 | 5.1% | 6 | 15.4% | 28 | 71.8% | 2 | 5.1% | 1 | 2.6% | . | . | . | . | 39 | 100.0% |
| Adenocarcinom | . | . | . | . | . | . | . | . | 2 | 66.7% | . | . | 1 | 33.3% | . | . | 3 | 100.0% |
| Skivepitelcancer | . | . | . | . | . | . | 3 | 100.0% | . | . | . | . | . | . | . | . | 3 | 100.0% |
| Totalt | 12 | 0.2% | 80 | 1.0% | 76 | 1.0% | 65 | 0.8% | 6 | 0.1% | 4 | 0.1% | 65 | 0.8% | 7500 | 96.1% | 7808 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=411 Lund

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|-----------|-------------|-----------|-------------|-----------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 290 | 0.6% | 2 | 0.0% | . | . | 2 | 0.0% | . | . | 1 | 0.0% | 9 | 0.0% | 45677 | 99.3% | 45981 | 100.0% |
| ASCUS | 171 | 12.6% | 48 | 3.5% | 13 | 1.0% | 20 | 1.5% | . | . | 1 | 0.1% | 27 | 2.0% | 1080 | 79.4% | 1360 | 100.0% |
| CIN1 | 158 | 15.5% | 117 | 11.5% | 42 | 4.1% | 57 | 5.6% | . | . | 3 | 0.3% | 41 | 4.0% | 602 | 59.0% | 1020 | 100.0% |
| Körtelcellsatypi | 13 | 41.9% | 2 | 6.5% | . | . | . | . | 3 | 9.7% | 2 | 6.5% | 2 | 6.5% | 9 | 29.0% | 31 | 100.0% |
| Atypi av oklar celltyp | 15 | 40.5% | 1 | 2.7% | 3 | 8.1% | 4 | 10.8% | . | . | . | . | 4 | 10.8% | 10 | 27.0% | 37 | 100.0% |
| ASC-H | 2 | 40.0% | . | . | . | . | 1 | 20.0% | . | . | . | . | 2 | 40.0% | . | . | 5 | 100.0% |
| CIN2 | 26 | 7.4% | 37 | 10.5% | 106 | 30.0% | 118 | 33.4% | 4 | 1.1% | 6 | 1.7% | 10 | 2.8% | 46 | 13.0% | 353 | 100.0% |
| CIN3 | 4 | 2.2% | 7 | 3.8% | 9 | 4.9% | 140 | 76.9% | 2 | 1.1% | 4 | 2.2% | 1 | 0.5% | 15 | 8.2% | 182 | 100.0% |
| Adenocarcinom | . | . | . | . | . | . | . | . | 8 | 61.5% | 3 | 23.1% | 1 | 7.7% | 1 | 7.7% | 13 | 100.0% |
| Skivepitelcancer | 1 | 20.0% | . | . | . | . | 2 | 40.0% | . | . | 1 | 20.0% | . | . | 1 | 20.0% | 5 | 100.0% |
| Totalt | 680 | 1.4% | 214 | 0.4% | 173 | 0.4% | 344 | 0.7% | 17 | 0.0% | 21 | 0.0% | 97 | 0.2% | 47441 | 96.8% | 48987 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=421 Halmstad

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|--------|-------|-------|-------|-------|-------|-------|-------|-------|--------|--------|-------|-------|-------|------------|-------|--------|--------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 95 | 0.6% | . | . | 2 | 0.0% | . | . | . | . | . | . | . | . | 15292 | 99.4% | 15389 | 100.0% |
| ASCUS | 99 | 30.7% | 38 | 11.8% | 18 | 5.6% | 9 | 2.8% | . | . | 2 | 0.6% | 1 | 0.3% | 155 | 48.1% | 322 | 100.0% |
| CIN1 | 67 | 31.3% | 37 | 17.3% | 33 | 15.4% | 9 | 4.2% | 1 | 0.5% | 1 | 0.5% | 7 | 3.3% | 59 | 27.6% | 214 | 100.0% |
| Körtelcellsatypi | 1 | 12.5% | . | . | 2 | 25.0% | 1 | 12.5% | . | . | 2 | 25.0% | 1 | 12.5% | 1 | 12.5% | 8 | 100.0% |
| Atypi av oklar celltyp | 1 | 16.7% | 1 | 16.7% | 1 | 16.7% | 1 | 16.7% | . | . | . | . | 1 | 16.7% | 1 | 16.7% | 6 | 100.0% |
| ASC-H | 2 | 12.5% | 2 | 12.5% | 4 | 25.0% | 6 | 37.5% | . | . | 1 | 6.3% | 1 | 6.3% | . | . | 16 | 100.0% |
| CIN2 | 7 | 13.0% | 3 | 5.6% | 21 | 38.9% | 18 | 33.3% | . | . | 3 | 5.6% | . | . | 2 | 3.7% | 54 | 100.0% |
| CIN3 | . | . | . | . | 2 | 20.0% | 8 | 80.0% | . | . | . | . | . | . | . | . | 10 | 100.0% |
| Adenocarcinom | . | . | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | 1 | 100.0% |
| Totalt | 272 | 1.7% | 81 | 0.5% | 83 | 0.5% | 52 | 0.3% | 2 | 0.0% | 9 | 0.1% | 11 | 0.1% | 15510 | 96.8% | 16020 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=431 Helsingborg

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|---------------------------------|------------|-------------|-----------|-------------|-----------|-------------|-----------|-------------|----------|-------------|-----------|-------------|-----------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 81 | 0.7% | 4 | 0.0% | 1 | 0.0% | . | . | . | . | 1 | 0.0% | 2 | 0.0% | 11354 | 99.2% | 11443 | 100.0% |
| ASCUS | 29 | 11.3% | 19 | 7.4% | 11 | 4.3% | 5 | 2.0% | . | . | . | . | 13 | 5.1% | 179 | 69.9% | 256 | 100.0% |
| CIN1 | 28 | 16.3% | 35 | 20.3% | 9 | 5.2% | 13 | 7.6% | . | . | 1 | 0.6% | 15 | 8.7% | 71 | 41.3% | 172 | 100.0% |
| Körtelcellsatypi | 3 | 33.3% | . | . | . | . | . | . | 3 | 33.3% | . | . | 2 | 22.2% | 1 | 11.1% | 9 | 100.0% |
| Atypi av oklar celltyp | 1 | 5.9% | 2 | 11.8% | 2 | 11.8% | 8 | 47.1% | 1 | 5.9% | 2 | 11.8% | . | . | 1 | 5.9% | 17 | 100.0% |
| ASC-H | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% |
| CIN2 | 3 | 4.4% | 6 | 8.8% | 25 | 36.8% | 28 | 41.2% | . | . | 1 | 1.5% | 2 | 2.9% | 3 | 4.4% | 68 | 100.0% |
| CIN3 | 2 | 4.7% | . | . | 2 | 4.7% | 31 | 72.1% | 1 | 2.3% | 4 | 9.3% | 1 | 2.3% | 2 | 4.7% | 43 | 100.0% |
| Adenocarcinom | . | . | . | . | . | . | . | . | 1 | 50.0% | . | . | . | . | 1 | 50.0% | 2 | 100.0% |
| Maligna celler av oklar celltyp | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | 1 | 100.0% |
| Skivepitelcancer | 1 | 33.3% | . | . | . | . | . | . | . | . | 2 | 66.7% | . | . | . | . | 3 | 100.0% |
| Totalt | 148 | 1.2% | 67 | 0.6% | 50 | 0.4% | 85 | 0.7% | 6 | 0.0% | 12 | 0.1% | 35 | 0.3% | 11612 | 96.6% | 12015 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=501 Göteborg

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|----------|-------------|-----------|-------------|-----------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 131 | 0.3% | 14 | 0.0% | 4 | 0.0% | 2 | 0.0% | . | . | . | . | 1 | 0.0% | 41001 | 99.6% | 41153 | 100.0% |
| ASCUS | 305 | 12.8% | 313 | 13.1% | 209 | 8.8% | 169 | 7.1% | 1 | 0.0% | 2 | 0.1% | 28 | 1.2% | 1355 | 56.9% | 2382 | 100.0% |
| CIN1 | 45 | 17.0% | 62 | 23.4% | 41 | 15.5% | 40 | 15.1% | . | . | . | . | 2 | 0.8% | 75 | 28.3% | 265 | 100.0% |
| Körtelcellsatypi | 4 | 28.6% | . | . | 2 | 14.3% | 3 | 21.4% | 2 | 14.3% | 1 | 7.1% | . | . | 2 | 14.3% | 14 | 100.0% |
| Atypi av oklar celltyp | . | . | . | . | . | . | 1 | 25.0% | . | . | . | . | . | . | 3 | 75.0% | 4 | 100.0% |
| ASC-H | 12 | 9.7% | 21 | 16.9% | 21 | 16.9% | 56 | 45.2% | . | . | 1 | 0.8% | 3 | 2.4% | 10 | 8.1% | 124 | 100.0% |
| CIN2 | 8 | 5.4% | 8 | 5.4% | 43 | 28.9% | 77 | 51.7% | . | . | 3 | 2.0% | 1 | 0.7% | 9 | 6.0% | 149 | 100.0% |
| CIN3 | 4 | 2.3% | 3 | 1.7% | 16 | 9.0% | 140 | 79.1% | . | . | 10 | 5.6% | . | . | 4 | 2.3% | 177 | 100.0% |
| Adenocarcinom | . | . | . | . | . | . | . | . | . | . | 2 | 100.0% | . | . | . | . | 2 | 100.0% |
| Skivepitelcancer | . | . | . | . | . | . | 1 | 50.0% | . | . | 1 | 50.0% | . | . | . | . | 2 | 100.0% |
| Totalt | 509 | 1.1% | 421 | 1.0% | 336 | 0.8% | 489 | 1.1% | 3 | 0.0% | 20 | 0.0% | 35 | 0.1% | 42459 | 95.9% | 44272 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=511 Trollhättan

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|------------|-------------|-----------|-------------|-----------|-------------|-----------|-------------|----------|-------------|----------|-------------|-----------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 78 | 0.5% | 1 | 0.0% | 1 | 0.0% | . | . | . | . | . | . | . | . | 14464 | 99.4% | 14544 | 100.0% |
| ASCUS | 61 | 21.9% | 41 | 14.7% | 20 | 7.2% | 6 | 2.2% | 1 | 0.4% | . | . | 6 | 2.2% | 143 | 51.4% | 278 | 100.0% |
| CIN1 | 39 | 22.7% | 27 | 15.7% | 24 | 14.0% | 13 | 7.6% | . | . | . | . | 6 | 3.5% | 63 | 36.6% | 172 | 100.0% |
| Körtelcellsatypi | 5 | 41.7% | . | . | 1 | 8.3% | 2 | 16.7% | . | . | 1 | 8.3% | . | . | 3 | 25.0% | 12 | 100.0% |
| Atypi av oklar celltyp | 1 | 100.0% | . | . | . | . | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% |
| CIN2 | 6 | 10.5% | 7 | 12.3% | 18 | 31.6% | 22 | 38.6% | 1 | 1.8% | . | . | . | . | 3 | 5.3% | 57 | 100.0% |
| CIN3 | 3 | 13.6% | . | . | 1 | 4.5% | 16 | 72.7% | 1 | 4.5% | 1 | 4.5% | . | . | . | . | 22 | 100.0% |
| Totalt | 193 | 1.3% | 76 | 0.5% | 65 | 0.4% | 59 | 0.4% | 3 | 0.0% | 2 | 0.0% | 12 | 0.1% | 14676 | 97.3% | 15086 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=521 Borås

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|--------|-------|-------|-------|-------|-------|-------|-------|-------|--------|--------|-------|-------|-------|------------|-------|--------|--------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 53 | 0.4% | . | . | 2 | 0.0% | . | . | . | . | . | . | . | . | 14900 | 99.6% | 14955 | 100.0% |
| ASCUS | 25 | 8.7% | 22 | 7.6% | 26 | 9.0% | 13 | 4.5% | . | . | 1 | 0.3% | 4 | 1.4% | 197 | 68.4% | 288 | 100.0% |
| CIN1 | 28 | 13.1% | 30 | 14.1% | 30 | 14.1% | 11 | 5.2% | . | . | . | . | 1 | 0.5% | 113 | 53.1% | 213 | 100.0% |
| Körtelcellsatypi | . | . | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | 1 | 100.0% |
| Atypi av oklar celltyp | 1 | 50.0% | . | . | . | . | . | . | . | . | . | . | . | . | 1 | 50.0% | 2 | 100.0% |
| CIN2 | 4 | 4.8% | 15 | 17.9% | 18 | 21.4% | 34 | 40.5% | 1 | 1.2% | 2 | 2.4% | . | . | 10 | 11.9% | 84 | 100.0% |
| CIN3 | . | . | . | . | 5 | 11.4% | 31 | 70.5% | 3 | 6.8% | 3 | 6.8% | . | . | 2 | 4.5% | 44 | 100.0% |
| Skivepitelcancer | . | . | . | . | 1 | 50.0% | 1 | 50.0% | . | . | . | . | . | . | . | . | 2 | 100.0% |
| Totalt | 111 | 0.7% | 67 | 0.4% | 82 | 0.5% | 90 | 0.6% | 5 | 0.0% | 6 | 0.0% | 5 | 0.0% | 15223 | 97.7% | 15589 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=531 Skövde

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|--------|--------|-------|-------|-------|-------|-------|-------|-------|-------|--------|-------|-------|-------|------------|-------|--------|--------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 74 | 0.5% | . | . | 1 | 0.0% | . | . | . | . | 1 | 0.0% | . | . | 13722 | 99.4% | 13798 | 100.0% |
| ASCUS | 96 | 15.0% | 19 | 3.0% | 25 | 3.9% | 22 | 3.4% | . | . | 1 | 0.2% | 1 | 0.2% | 475 | 74.3% | 639 | 100.0% |
| CIN1 | 78 | 33.3% | 33 | 14.1% | 24 | 10.3% | 25 | 10.7% | 1 | 0.4% | 1 | 0.4% | . | . | 72 | 30.8% | 234 | 100.0% |
| Körtelcellsatypi | 2 | 100.0% | . | . | . | . | . | . | . | . | . | . | . | . | . | . | 2 | 100.0% |
| Atypi av oklar celltyp | . | . | 1 | 50.0% | . | . | . | . | . | . | . | . | . | . | 1 | 50.0% | 2 | 100.0% |
| ASC-H | 2 | 7.1% | 4 | 14.3% | 3 | 10.7% | 17 | 60.7% | 1 | 3.6% | . | . | . | . | 1 | 3.6% | 28 | 100.0% |
| CIN2 | 8 | 12.5% | 5 | 7.8% | 16 | 25.0% | 28 | 43.8% | . | . | 4 | 6.3% | . | . | 3 | 4.7% | 64 | 100.0% |
| CIN3 | 1 | 6.3% | . | . | 1 | 6.3% | 11 | 68.8% | . | . | 2 | 12.5% | . | . | 1 | 6.3% | 16 | 100.0% |
| Totalt | 261 | 1.8% | 62 | 0.4% | 70 | 0.5% | 103 | 0.7% | 2 | 0.0% | 9 | 0.1% | 1 | 0.0% | 14275 | 96.6% | 14783 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=541 Karlstad

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|----------|-------------|-----------|-------------|-----------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 119 | 0.7% | 20 | 0.1% | 5 | 0.0% | 6 | 0.0% | . | . | . | . | 6 | 0.0% | 16054 | 99.0% | 16210 | 100.0% |
| ASCUS | 34 | 6.7% | 83 | 16.3% | 36 | 7.1% | 39 | 7.7% | . | . | 2 | 0.4% | 7 | 1.4% | 307 | 60.4% | 508 | 100.0% |
| CIN1 | 33 | 11.0% | 86 | 28.6% | 34 | 11.3% | 33 | 11.0% | 1 | 0.3% | . | . | 1 | 0.3% | 113 | 37.5% | 301 | 100.0% |
| Körtelcellsatypi | 8 | 53.3% | 2 | 13.3% | . | . | 3 | 20.0% | . | . | 2 | 13.3% | . | . | . | . | 15 | 100.0% |
| Atypi av oklar celltyp | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% |
| ASC-H | 2 | 10.0% | 3 | 15.0% | 5 | 25.0% | 8 | 40.0% | . | . | . | . | . | . | 2 | 10.0% | 20 | 100.0% |
| CIN2 | 6 | 7.6% | 18 | 22.8% | 15 | 19.0% | 36 | 45.6% | . | . | 1 | 1.3% | 1 | 1.3% | 2 | 2.5% | 79 | 100.0% |
| CIN3 | 2 | 1.9% | 5 | 4.8% | 8 | 7.6% | 75 | 71.4% | 6 | 5.7% | 7 | 6.7% | . | . | 2 | 1.9% | 105 | 100.0% |
| Adenocarcinom | . | . | . | . | . | . | 2 | 33.3% | 2 | 33.3% | 2 | 33.3% | . | . | . | . | 6 | 100.0% |
| Skivepitelcancer | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | 1 | 100.0% |
| Totalt | 204 | 1.2% | 217 | 1.3% | 104 | 0.6% | 203 | 1.2% | 9 | 0.1% | 14 | 0.1% | 15 | 0.1% | 16480 | 95.6% | 17246 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=551 Örebro

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|------------|-------------|-----------|-------------|------------|-------------|-----------|-------------|----------|-------------|----------|-------------|-----------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 50 | 0.3% | 1 | 0.0% | . | . | . | . | . | . | . | . | 1 | 0.0% | 14936 | 99.7% | 14988 | 100.0% |
| ASCUS | 34 | 5.7% | 23 | 3.9% | 19 | 3.2% | 4 | 0.7% | 1 | 0.2% | 1 | 0.2% | 9 | 1.5% | 505 | 84.7% | 596 | 100.0% |
| CIN1 | 29 | 9.9% | 27 | 9.2% | 29 | 9.9% | 4 | 1.4% | . | . | 1 | 0.3% | 11 | 3.8% | 191 | 65.4% | 292 | 100.0% |
| Körtelcellsatypi | 1 | 20.0% | . | . | . | . | 1 | 20.0% | 3 | 60.0% | . | . | . | . | . | . | 5 | 100.0% |
| Atypi av oklar celltyp | 3 | 42.9% | 1 | 14.3% | 1 | 14.3% | . | . | . | . | . | . | . | . | 2 | 28.6% | 7 | 100.0% |
| ASC-H | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% |
| CIN2 | 2 | 2.1% | 8 | 8.2% | 64 | 66.0% | 13 | 13.4% | 1 | 1.0% | 3 | 3.1% | 1 | 1.0% | 5 | 5.2% | 97 | 100.0% |
| CIN3 | 1 | 4.8% | . | . | 6 | 28.6% | 13 | 61.9% | 1 | 4.8% | . | . | . | . | . | . | 21 | 100.0% |
| Skivepitelcancer | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | 1 | 100.0% |
| Totalt | 120 | 0.7% | 60 | 0.4% | 120 | 0.7% | 35 | 0.2% | 6 | 0.0% | 6 | 0.0% | 22 | 0.1% | 15639 | 97.7% | 16008 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=561 Västerås

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|------------|-------------|-----------|-------------|-----------|-------------|-----------|-------------|----------|-------------|----------|-------------|-----------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 60 | 0.5% | . | . | . | . | . | . | . | . | . | . | 1 | 0.0% | 12387 | 99.5% | 12448 | 100.0% |
| ASCUS | 65 | 30.4% | 30 | 14.0% | 19 | 8.9% | 17 | 7.9% | 2 | 0.9% | . | . | 5 | 2.3% | 76 | 35.5% | 214 | 100.0% |
| CIN1 | 39 | 28.3% | 19 | 13.8% | 15 | 10.9% | 11 | 8.0% | . | . | 1 | 0.7% | 10 | 7.2% | 43 | 31.2% | 138 | 100.0% |
| Körtelcellsatypi | 3 | 60.0% | 1 | 20.0% | . | . | 1 | 20.0% | . | . | . | . | . | . | . | . | 5 | 100.0% |
| Atypi av oklar celltyp | 3 | 42.9% | 1 | 14.3% | 1 | 14.3% | . | . | . | . | . | . | 1 | 14.3% | 1 | 14.3% | 7 | 100.0% |
| CIN2 | 5 | 7.0% | 6 | 8.5% | 27 | 38.0% | 28 | 39.4% | . | . | . | . | 1 | 1.4% | 4 | 5.6% | 71 | 100.0% |
| CIN3 | 1 | 6.3% | 1 | 6.3% | 1 | 6.3% | 12 | 75.0% | . | . | . | . | . | . | 1 | 6.3% | 16 | 100.0% |
| Totalt | 176 | 1.4% | 58 | 0.4% | 63 | 0.5% | 69 | 0.5% | 2 | 0.0% | 1 | 0.0% | 18 | 0.1% | 12512 | 97.0% | 12899 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=571 Dalarna

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|--------|-------|-------|-------|-------|--------|-------|-------|-------|-------|--------|-------|-------|-------|------------|-------|--------|--------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 79 | 0.5% | 13 | 0.1% | . | . | 1 | 0.0% | . | . | . | . | . | . | 14447 | 99.4% | 14540 | 100.0% |
| ASCUS | 8 | 2.7% | 46 | 15.7% | 21 | 7.2% | 14 | 4.8% | . | . | . | . | 1 | 0.3% | 203 | 69.3% | 293 | 100.0% |
| CIN1 | 8 | 3.7% | 53 | 24.5% | 39 | 18.1% | 20 | 9.3% | . | . | . | . | . | . | 96 | 44.4% | 216 | 100.0% |
| Körtelcellsatypi | 1 | 14.3% | 1 | 14.3% | 3 | 42.9% | . | . | . | . | . | . | . | . | 2 | 28.6% | 7 | 100.0% |
| Atypi av oklar celltyp | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% |
| ASC-H | . | . | 3 | 10.7% | 7 | 25.0% | 15 | 53.6% | . | . | 2 | 7.1% | . | . | 1 | 3.6% | 28 | 100.0% |
| CIN2 | 2 | 5.4% | 4 | 10.8% | 13 | 35.1% | 17 | 45.9% | . | . | . | . | . | . | 1 | 2.7% | 37 | 100.0% |
| CIN3 | . | . | 1 | 5.3% | 2 | 10.5% | 14 | 73.7% | 1 | 5.3% | 1 | 5.3% | . | . | . | . | 19 | 100.0% |
| Totalt | 98 | 0.6% | 121 | 0.8% | 86 | 0.6% | 81 | 0.5% | 1 | 0.0% | 3 | 0.0% | 1 | 0.0% | 14750 | 97.4% | 15141 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=611 Gävle

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|--------|-------|-------|-------|-------|-------|-------|--------|-------|-------|--------|-------|-------|-------|------------|--------|--------|--------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 44 | 0.3% | 5 | 0.0% | 1 | 0.0% | 3 | 0.0% | . | . | 1 | 0.0% | 1 | 0.0% | 15037 | 99.6% | 15092 | 100.0% |
| ASCUS | 50 | 11.4% | 23 | 5.2% | 30 | 6.8% | 36 | 8.2% | 1 | 0.2% | 4 | 0.9% | 7 | 1.6% | 288 | 65.6% | 439 | 100.0% |
| CIN1 | 11 | 12.2% | 9 | 10.0% | 7 | 7.8% | 28 | 31.1% | . | . | 1 | 1.1% | 1 | 1.1% | 33 | 36.7% | 90 | 100.0% |
| Atypi av oklar celltyp | . | . | . | . | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% | 1 | 100.0% |
| CIN2 | 1 | 4.3% | 4 | 17.4% | . | . | 16 | 69.6% | . | . | . | . | . | . | 2 | 8.7% | 23 | 100.0% |
| CIN3 | . | . | . | . | . | . | 2 | 100.0% | . | . | . | . | . | . | . | . | 2 | 100.0% |
| Totalt | 106 | 0.7% | 41 | 0.3% | 38 | 0.2% | 85 | 0.5% | 1 | 0.0% | 6 | 0.0% | 9 | 0.1% | 15361 | 98.2% | 15647 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=621 Sundsvall

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|--------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|-------|-------|-------|------------|-------|--------|--------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 46 | 0.5% | 3 | 0.0% | 2 | 0.0% | . | . | . | . | . | . | 2 | 0.0% | 10063 | 99.5% | 10116 | 100.0% |
| ASCUS | 88 | 17.3% | 50 | 9.8% | 24 | 4.7% | 14 | 2.8% | 4 | 0.8% | . | . | 4 | 0.8% | 325 | 63.9% | 509 | 100.0% |
| CIN1 | 55 | 23.9% | 48 | 20.9% | 33 | 14.3% | 18 | 7.8% | . | . | 1 | 0.4% | 2 | 0.9% | 73 | 31.7% | 230 | 100.0% |
| Körtelcellsatypi | 20 | 74.1% | 1 | 3.7% | . | . | 1 | 3.7% | 1 | 3.7% | 1 | 3.7% | . | . | 3 | 11.1% | 27 | 100.0% |
| Atypi av oklar celltyp | 10 | 47.6% | 1 | 4.8% | 2 | 9.5% | 6 | 28.6% | 1 | 4.8% | . | . | 1 | 4.8% | . | . | 21 | 100.0% |
| ASC-H | 1 | 14.3% | . | . | . | . | 4 | 57.1% | . | . | 1 | 14.3% | . | . | 1 | 14.3% | 7 | 100.0% |
| CIN2 | 7 | 14.9% | 5 | 10.6% | 10 | 21.3% | 19 | 40.4% | . | . | 1 | 2.1% | . | . | 5 | 10.6% | 47 | 100.0% |
| CIN3 | . | . | 1 | 5.0% | 1 | 5.0% | 16 | 80.0% | 1 | 5.0% | 1 | 5.0% | . | . | . | . | 20 | 100.0% |
| Totalt | 227 | 2.1% | 109 | 1.0% | 72 | 0.7% | 78 | 0.7% | 7 | 0.1% | 5 | 0.0% | 9 | 0.1% | 10470 | 95.4% | 10977 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=631 Jämtland

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | | |
|------------------------|------------|-------------|-----------|-------------|-----------|-------------|-----------|-------------|----------|-------------|----------|-------------|-----------|-------------|-------------|--------------|-------------|---------------|--------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | |
| Benigt prov | 34 | 0.7% | . | . | . | . | . | . | . | . | . | . | 2 | 0.0% | 4988 | 99.3% | 5024 | 100.0% | |
| ASCUS | 50 | 17.4% | 34 | 11.8% | 9 | 3.1% | 10 | 3.5% | . | . | 1 | 0.3% | 2 | 0.7% | 181 | 63.1% | 287 | 100.0% | |
| CIN1 | 28 | 23.7% | 32 | 27.1% | 4 | 3.4% | 14 | 11.9% | . | . | . | . | 3 | 2.5% | 37 | 31.4% | 118 | 100.0% | |
| Körtelcellsatypi | 6 | 60.0% | . | . | . | . | 3 | 30.0% | . | . | . | . | 1 | 10.0% | . | . | 10 | 100.0% | |
| Atypi av oklar celltyp | 4 | 50.0% | . | . | . | . | 1 | 12.5% | . | . | . | . | 3 | 37.5% | . | . | 8 | 100.0% | |
| ASC-H | 1 | 8.3% | 1 | 8.3% | 2 | 16.7% | 7 | 58.3% | 1 | 8.3% | . | . | . | . | . | . | 12 | 100.0% | |
| CIN2 | 5 | 11.6% | 2 | 4.7% | 6 | 14.0% | 29 | 67.4% | . | . | 1 | 2.3% | . | . | . | . | 43 | 100.0% | |
| CIN3 | . | . | . | . | . | . | 15 | 100.0% | . | . | . | . | . | . | . | . | . | 15 | 100.0% |
| Adenocarcinom | . | . | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | 1 | 100.0% |
| Skivepitelcancer | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | . | 1 | 100.0% |
| Totalt | 128 | 2.3% | 69 | 1.3% | 21 | 0.4% | 79 | 1.4% | 2 | 0.0% | 3 | 0.1% | 11 | 0.2% | 5206 | 94.3% | 5519 | 100.0% | |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=641 Umeå

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|---------------------------------|------------|-------------|------------|-------------|-----------|-------------|------------|-------------|----------|-------------|----------|-------------|-----------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 41 | 0.3% | 3 | 0.0% | . | . | . | . | . | . | 1 | 0.0% | . | . | 12615 | 99.6% | 12660 | 100.0% |
| ASCUS | 85 | 10.6% | 93 | 11.6% | 9 | 1.1% | 19 | 2.4% | . | . | . | . | 12 | 1.5% | 584 | 72.8% | 802 | 100.0% |
| CIN1 | 69 | 20.1% | 90 | 26.2% | 23 | 6.7% | 35 | 10.2% | . | . | . | . | 7 | 2.0% | 120 | 34.9% | 344 | 100.0% |
| Körtelcellsatypi | 8 | 42.1% | 1 | 5.3% | . | . | 5 | 26.3% | . | . | . | . | 2 | 10.5% | 3 | 15.8% | 19 | 100.0% |
| Atypi av oklar celltyp | 2 | 15.4% | 1 | 7.7% | . | . | 3 | 23.1% | 1 | 7.7% | . | . | 3 | 23.1% | 3 | 23.1% | 13 | 100.0% |
| ASC-H | 4 | 11.8% | 10 | 29.4% | 2 | 5.9% | 14 | 41.2% | . | . | . | . | 2 | 5.9% | 2 | 5.9% | 34 | 100.0% |
| CIN2 | 10 | 10.2% | 20 | 20.4% | 11 | 11.2% | 43 | 43.9% | 2 | 2.0% | 1 | 1.0% | 5 | 5.1% | 6 | 6.1% | 98 | 100.0% |
| CIN3 | . | . | 1 | 2.4% | 3 | 7.3% | 33 | 80.5% | . | . | 2 | 4.9% | . | . | 2 | 4.9% | 41 | 100.0% |
| Adenocarcinom | . | . | 1 | 20.0% | . | . | . | . | 2 | 40.0% | 1 | 20.0% | 1 | 20.0% | . | . | 5 | 100.0% |
| Maligna celler av oklar celltyp | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | 1 | 100.0% |
| Totalt | 219 | 1.6% | 220 | 1.6% | 48 | 0.3% | 153 | 1.1% | 5 | 0.0% | 5 | 0.0% | 32 | 0.2% | 13335 | 95.1% | 14017 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=651 Sunderby

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|------------------------|------------|-------------|-----------|-------------|-----------|-------------|------------|-------------|----------|-------------|----------|-------------|-----------|-------------|--------------|--------------|--------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 45 | 0.4% | 1 | 0.0% | . | . | . | . | . | . | . | . | 1 | 0.0% | 11649 | 99.6% | 11696 | 100.0% |
| ASCUS | 39 | 16.4% | 24 | 10.1% | 17 | 7.1% | 32 | 13.4% | . | . | . | . | 9 | 3.8% | 117 | 49.2% | 238 | 100.0% |
| CIN1 | 25 | 23.6% | 15 | 14.2% | 17 | 16.0% | 16 | 15.1% | 1 | 0.9% | . | . | 6 | 5.7% | 26 | 24.5% | 106 | 100.0% |
| Körtelcellsatypi | 1 | 33.3% | . | . | . | . | . | . | . | . | 1 | 33.3% | 1 | 33.3% | . | . | 3 | 100.0% |
| Atypi av oklar celltyp | . | . | . | . | 1 | 11.1% | 3 | 33.3% | 1 | 11.1% | . | . | . | . | 4 | 44.4% | 9 | 100.0% |
| ASC-H | 1 | 7.1% | 1 | 7.1% | . | . | 11 | 78.6% | . | . | . | . | . | . | 1 | 7.1% | 14 | 100.0% |
| CIN2 | 6 | 11.1% | 2 | 3.7% | 3 | 5.6% | 37 | 68.5% | 1 | 1.9% | 2 | 3.7% | . | . | 3 | 5.6% | 54 | 100.0% |
| CIN3 | 1 | 1.8% | . | . | . | . | 49 | 87.5% | 1 | 1.8% | 4 | 7.1% | 1 | 1.8% | . | . | 56 | 100.0% |
| Adenocarcinom | . | . | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | 1 | 100.0% |
| Skivepitelcancer | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | 1 | 100.0% |
| Totalt | 118 | 1.0% | 43 | 0.4% | 38 | 0.3% | 149 | 1.2% | 5 | 0.0% | 7 | 0.1% | 18 | 0.1% | 11800 | 96.9% | 12178 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.

NKCx - Histopatologiskt utfall inom 12 månader efter cervixcytologi från 2015
Organiserad screening

Lab=Hela Riket

| Cytologi | Benigt | | CIN1 | | CIN2 | | CIN3 | | AIS | | Cancer | | Annat | | PAD Saknas | | Totalt | |
|---------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|------------|-------------|------------|-------------|------------|-------------|---------------|--------------|---------------|---------------|
| | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benigt prov | 2080 | 0.5% | 138 | 0.0% | 48 | 0.0% | 24 | 0.0% | 1 | 0.0% | 10 | 0.0% | 94 | 0.0% | 433521 | 99.5% | 435916 | 100.0% |
| ASCUS | 1737 | 12.6% | 1539 | 11.1% | 815 | 5.9% | 707 | 5.1% | 19 | 0.1% | 22 | 0.2% | 368 | 2.7% | 8628 | 62.4% | 13835 | 100.0% |
| CIN1 | 1244 | 16.7% | 1606 | 21.5% | 785 | 10.5% | 700 | 9.4% | 12 | 0.2% | 20 | 0.3% | 328 | 4.4% | 2772 | 37.1% | 7467 | 100.0% |
| Körtelcellsatypi | 161 | 35.9% | 45 | 10.0% | 37 | 8.3% | 69 | 15.4% | 32 | 7.1% | 22 | 4.9% | 34 | 7.6% | 48 | 10.7% | 448 | 100.0% |
| Atypi av oklar celltyp | 54 | 27.3% | 19 | 9.6% | 19 | 9.6% | 45 | 22.7% | 4 | 2.0% | 2 | 1.0% | 17 | 8.6% | 38 | 19.2% | 198 | 100.0% |
| ASC-H | 38 | 7.2% | 75 | 14.2% | 95 | 18.0% | 262 | 49.5% | 7 | 1.3% | 13 | 2.5% | 16 | 3.0% | 23 | 4.3% | 529 | 100.0% |
| CIN2 | 182 | 7.3% | 254 | 10.2% | 676 | 27.2% | 1115 | 44.8% | 19 | 0.8% | 49 | 2.0% | 52 | 2.1% | 140 | 5.6% | 2487 | 100.0% |
| CIN3 | 27 | 2.1% | 31 | 2.4% | 95 | 7.4% | 998 | 77.8% | 25 | 1.9% | 66 | 5.1% | 6 | 0.5% | 35 | 2.7% | 1283 | 100.0% |
| Adenocarcinom | 4 | 5.3% | 4 | 5.3% | . | . | 13 | 17.1% | 28 | 36.8% | 20 | 26.3% | 4 | 5.3% | 3 | 3.9% | 76 | 100.0% |
| Maligna celler av oklar celltyp | . | . | . | . | . | . | 1 | 50.0% | . | . | 1 | 50.0% | . | . | . | . | 2 | 100.0% |
| Skivepitelcancer | 2 | 5.4% | . | . | 1 | 2.7% | 15 | 40.5% | . | . | 17 | 45.9% | . | . | 2 | 5.4% | 37 | 100.0% |
| Totalt | 5529 | 1.2% | 3711 | 0.8% | 2571 | 0.6% | 3949 | 0.9% | 147 | 0.0% | 242 | 0.1% | 919 | 0.2% | 445210 | 96.3% | 462278 | 100.0% |

Denna lista inkluderar endast EN diagnos (den högst rankade) per person, gäller både Cyt och Pad.
Endast PAD Topo T83x medräknade.